| Market Cap | 49.81M | P/E | - | EPS this Y | - | Ern Qtrly Grth | - |
| Income | -4.13M | Forward P/E | -17.28 | EPS next Y | 23.10% | 50D Avg Chg | 29.00% |
| Sales | 507.74k | PEG | - | EPS past 5Y | - | 200D Avg Chg | 29.00% |
| Dividend | N/A | Price/Book | 61.71 | EPS next 5Y | - | 52W High Chg | -53.00% |
| Recommedations | 2.00 | Quick Ratio | 12.83 | Shares Outstanding | 11.54M | 52W Low Chg | 83.00% |
| Insider Own | 70.73% | ROA | -27.30% | Shares Float | 1.70M | Beta | - |
| Inst Own | 0.08% | ROE | -69.87% | Shares Shorted/Prior | 39.35K/19.26K | Price | 4.32 |
| Gross Margin | 99.27% | Profit Margin | - | Avg. Volume | 501,425 | Target Price | - |
| Oper. Margin | -811.27% | Earnings Date | - | Volume | 59,734 | Change | 3.35% |
CytoMed Therapeutics Limited, a pre-clinical biopharmaceutical company, focuses on developing novel cell-based immunotherapies for the treatment of human cancers in Malaysia and Singapore. Its lead product candidate is CTM-N2D, which is in Phase I clinical trials comprising expanded gamma delta T cells grafted with natural killer group 2D ligands-targeting chimeric antigen receptor to improve anti-cancer cytotoxicity. The company is also developing iPSC-gdNKT, which utilizes iPSC as a starting material to generate gdNKT, a synthetic hybrid of a gamma delta T cell and a NK cell; and CTM-GDT, a product candidate that consists of expanded gamma delta T cells and exploits the multiple recognition system of gamma delta T cell to recognize and treat a range of cancers. It has research collaboration agreement with Sengkang General Hospital Pte Ltd to establish proof-of-concept use of an injectable cartilage regeneration therapy that has been developed with donor-sourced, (allogeneic) umbilical cord-derived mesenchymal stem cells (UC-MSCs) to treat cartilage injury. The company was incorporated in 2018 and is headquartered in Singapore.
| Benchmark | Speculative Buy | Dec 4, 23 |
| Benchmark | Speculative Buy | Jul 21, 23 |